Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Vancomycin and metronidazole remain the only primary options for the treatment of Clostridium difficile infection (CDI). Recent reports have suggested a superior clinical response to vancomycin therapy compared with metronidazole, but this has been difficult to prove or explain. There are few robust in vitro data of the effects of antibiotic treatment of CDI in a gut reflective setting. METHODS: We used clindamycin to induce high-level toxin production by two epidemic C. difficile PCR ribotypes in a human gut model of CDI. Vancomycin was instilled into the models to achieve in vivo faecal concentrations. C. difficile populations and toxin titres, and gut bacterial populations and vancomycin levels were monitored before, during and after vancomycin instillation. RESULTS: Clindamycin treatment elicited C. difficile germination and high-level cytotoxin production. Vancomycin reduced total viable counts and cytotoxin titres of both C. difficile PCR ribotypes, with no evidence of recurrence before the model runs were ended. C. difficile PCR ribotype 027 populations exhibited greater germination capacity than did PCR ribotype 106. Vancomycin was more rapidly effective against the greater numbers of PCR ribotype 027 vegetative forms. Vancomycin showed no activity against C. difficile spores. CONCLUSIONS: Bacteriological response to vancomycin varies between strains causing CDI, possibly correlating with the extent of germination capacity. Vancomycin effectively reduced vegetative forms and cytotoxin titres of both of the epidemic C. difficile PCR ribotypes evaluated, but showed no anti-spore activity. Comparison with the results of a previous gut model study showed that vancomycin was more effective than metronidazole in reducing C. difficile PCR ribotype 027 numbers and cytotoxin titres.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macfarlane, G. T., Macfarlane, S., & Gibson, G. R. (1998) · Microbial Ecology · doi:10.1007/s002489900072 · Cited by 539 · cited 2×
“The gut model was developed and validated against the caecal contents of sudden death victims by MacFarlane et al.18 We have previously described its modification and use as a model of CDI.12–16 Briefly, the gut model comprises three fermentation vessels top-fed by growth medium at a controlled rate (D¼ 0.015 h21) and…”
MethodInfluential
Cited by
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380
Clostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Self-citationAntibiotic perturbations to the gut microbiome
Fishbein, S. R. S., Mahmud, B., & Dantas, G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00933-y · Cited by 440
Clostridium difficile spore biology: sporulation, germination, and spore structural proteins
Paredes-Sabja, D., Shen, A., & Sorg, J. A. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.003 · Cited by 419
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., & Gorbach, S. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis462 · Cited by 401
Metadata
- Authors
- Baines, S. D., O'Connor, R., Saxton, K., Freeman, J., & Wilcox, M. H.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-15
- Volume
- 63
- Issue
- 3
- Pages
- 520-525
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2167016769
- Cited by
- 79
- References
- 1
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.